asia-pacific-cancer-therapies-market-industry
Published

November 2016

Asia-Pacific Cancer Therapy Market - Growth, Trends, and Forecasts (2016- 2021)

Purchase Report
$3850
Single user license
$4000
Team license
$8250
Corporate license

The Asia-Pacific market for cancer therapy was estimated at USD 4.6 billion for the year 2016 and is projected to reach USD 9 billion by the end of 2021 at a CAGR of 13.9 % during the forecast period from 2016 to 2021.

According to the World Health Organization (WHO), more than 6 million new cancer cases are diagnosed in Asia every year. Cancer is the leading cause of death and the incidence rates are increasing annually. Due to this, the demand for quality cancer treatments has risen dramatically, which is contributing to the growth of the market.

Asia-Pacific Cancer Therapy Market-Market Dynamics

The end-users of this market are clinics, hospitals, and research centers. Lung cancer, breast cancer, colorectal cancer, ovarian cancer, head & neck cancer, stomach cancer and liver cancer are some of the common cancers increasing the treatment options in Asia.

Drivers

  • Increasing incidence of cancer
  • Aging population
  • Growing demand for advanced therapies
  • Patent expiry of leading drugs
  • Government initiatives
  • Increasing public awareness about diseases and treatment options

Restraints

  • High prices of therapies
  • Side-effects caused during treatment
  • Change in reimbursement policies
  • Stringent regulations

The market for cancer therapy in Asia-Pacific is segmented based on the type of therapy, which includes chemotherapy (marketed drugs and drugs in the pipeline), radiotherapy, surgery, hormone therapy, targeted cancer therapy, immunotherapy (monoclonal antibodies, cancer vaccines, and non-specific immunotherapy) and combination therapy. Chemotherapy, radiation therapy, and combinational therapy are increasingly available in the Asia-Pacific region. However, chemotherapy is the largest segment of APAC cancer therapeutics market.

Many players in this market are trying to expand their product portfolio in order to top the global market. While a few companies are entering the market by acquisitions, top companies are expanding their growth by acquiring other companies. Some companies have adopted product innovation and new product launches as their key business strategy to ensure their dominance in this market. Roche is developing a large number of combinational therapies.

Some of the key players in the market are:

  • AstraZeneca
  • Bristol-Myers Squibb
  • Celgene
  • Janssen
  • Merck
  • Novartis
  • Pfizer
  • Teva

Key Deliverables in the Study

  • Market analysis for the Asia-Pacific cancer therapy market, with region-specific assessments and competition analysis on the global and regional scale.
  • Market definition along with the identification of key drivers and restraints.
  • Identification of factors instrumental in changing the market scenario, rising prospective opportunities, and identification of key companies that can influence this market on a global and regional scale.
  • Extensively researched competitive landscape section with profiles of major companies along with their market share.
  • Identification and analysis of the macro and micro factors that affect the Asia-Pacific cancer therapy market on both global and regional scale.
  • A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information.
  • A wide-ranging knowledge and insights about the major players in this industry and the key strategies adopted by them to sustain and grow in the studied market.
  • Insights on the major countries/regions in which this industry is growing and to also identify the regions that are still untapped.
RELATED REPORTS

Confused about which report to get?

Download a full report to understand our capabilities
Purchase Report
$3850
Single user license
$4000
Team license
$8250
Corporate license
Our Clients Include View All

Looking to Customize Report?